|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2005-10-5
|
|
pubmed:abstractText |
Replacement of the aryl piperazine moiety in compound 1 with a variety of substituted benzylic piperazines (6) yields compounds that afford melanocortin receptor 4 (MCR4) activity. Analogs with ortho substitution on the aromatic ring afforded the highest affinity. Resolution of the stereocenter of the benzylic piperazine based privileged structure revealed that the R-enantiomer was more active.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:BackerRyan TRT,
pubmed-author:BrinerKarinK,
pubmed-author:ColladoIvánI,
pubmed-author:FisherMatthew JMJ,
pubmed-author:HsiungHansen MHM,
pubmed-author:HusainSabaS,
pubmed-author:KuklishSteve LSL,
pubmed-author:MateoAna IAI,
pubmed-author:MullaneyJeffrey TJT,
pubmed-author:O'BrianThomas PTP,
pubmed-author:OrnsteinPaul LPL,
pubmed-author:ParedesCristina GarcíaCG,
pubmed-author:RichardsonTimothy ITI,
pubmed-author:ShahJikeshJ,
pubmed-author:ZgombickJohn MJM,
pubmed-author:de FrutosOscarO
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4973-8
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Privileged structure based ligands for melanocortin receptors--substituted benzylic piperazine derivatives.
|
|
pubmed:affiliation |
Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46258, USA. fisher_matthew_j@lilly.com
|
|
pubmed:publicationType |
Journal Article
|
